Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

NMRA

Neumora Therapeutics Inc.

Jul 26 • 04:00PM ET

12.90

Dollar change +0.49
Percentage change 3.95	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: IWM VTI IWO VTWO VXF SBIO SCHA ONEQ VTWG RSSL

Index	RUT	P/E	-	EPS (ttm)	-1.62	Insider Own	65.80%	Shs Outstand	158.83M	Perf Week	14.36%
Market Cap	2.06B	Forward P/E	-	EPS next Y	-1.58	Insider Trans	0.00%	Shs Float	54.56M	Perf Month	50.00%
Income	-254.02M	PEG	-	EPS next Q	-0.37	Inst Own	20.41%	Short Float	16.24%	Perf Quarter	42.38%
Sales	0.00M	P/S	-	EPS this Y	59.15%	Inst Trans	-	Short Ratio	11.07	Perf Half Y	-14.57%
Book/sh	2.66	P/B	4.84	EPS next Y	-6.52%	ROA	-60.32%	Short Interest	8.86M	Perf Year	-
Cash/sh	2.65	P/C	4.87	EPS next 5Y	-	ROE	-64.28%	52W Range	8.33 - 21.00	Perf YTD	-24.34%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-59.70%	52W High	-38.57%	Beta	-
Dividend TTM	-	Quick Ratio	17.99	Sales past 5Y	0.00%	Gross Margin	-	52W Low	54.86%	ATR (14)	0.67
Dividend Ex-Date	-	Current Ratio	17.99	EPS Y/Y TTM	-99.66%	Oper. Margin	0.00%	RSI (14)	70.65	Volatility	5.96% 6.19%
Employees	124	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	23.26
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-43.81%	Payout	-	Rel Volume	0.47	Prev Close	12.41
Sales Surprise	-	EPS Surprise	0.58%	Sales Q/Q	-	Earnings	May 07 BMO	Avg Volume	800.67K	Price	12.90
SMA20	18.17%	SMA50	27.45%	SMA200	1.11%	Trades		Volume	378,705	Change	3.95%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-22-24	Initiated	Needham	Buy	$23
Jul-08-24	Initiated	Mizuho	Outperform	$20
Dec-12-23	Initiated	Deutsche Bank	Hold	$13
Oct-10-23	Initiated	William Blair	Outperform	$26
Oct-10-23	Initiated	Stifel	Buy	$26
Oct-10-23	Initiated	RBC Capital Mkts	Outperform	$24
Oct-10-23	Initiated	JP Morgan	Overweight	$21
Oct-10-23	Initiated	Guggenheim	Buy	$22
Oct-10-23	Initiated	BofA Securities	Buy	$18

Jul-01-24 01:00AM	10 clinical trials to watch in the second half of 2024 (BioPharma Dive)
Jun-20-24 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation (GlobeNewswire)
May-14-24 08:52AM	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression (MT Newswires) +6.92%
07:00AM	Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression (GlobeNewswire)
May-07-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024 (InvestorPlace)
10:20AM	Loading…
10:20AM	Neumora Therapeutics Shares Fall as Q1 Loss Narrows (MT Newswires)
07:00AM	Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in May (GlobeNewswire)
Apr-16-24 11:28AM	Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug (Zacks)
Apr-15-24 04:20PM	Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug (Investor's Business Daily) -17.48%
12:17PM	Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday? (Benzinga)
08:45AM	Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today? (InvestorPlace)
07:47AM	Neumoras schizophrenia drug hit with clinical hold (BioPharma Dive)
06:36AM	U.S. FDA places clinical hold on Neumora's schizophrenia drug study (Reuters)
06:30AM	Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study (GlobeNewswire)
07:00AM	Loading…
Mar-13-24 07:00AM	Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days (GlobeNewswire) -14.64%
Mar-07-24 02:52PM	NMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jan-22-24 07:00AM	Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer (GlobeNewswire) +9.89%
Jan-10-24 08:32AM	Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick (Zacks)
Jan-02-24 07:00AM	Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-17-23 12:35PM	7 Stocks with Strong Insider Buying: December 2023 (InvestorPlace)
Dec-12-23 07:00AM	Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer (GlobeNewswire)
Nov-27-23 07:00AM	Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study (GlobeNewswire)
Nov-01-23 07:00AM	Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) -6.00%
Oct-10-23 07:00AM	Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development (GlobeNewswire) -6.45%
Sep-28-23 07:54PM	Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO) (InvestorPlace) +11.84% +6.73%
Sep-27-23 06:50PM	Tracking 2023's Largest IPOs: Instacart, Arm, Birkenstock and More (Updated November) (Observer)
Sep-18-23 12:35PM	UPDATE 3-Marketing firm Klaviyo lifts IPO price range, targets $9 bln valuation (Reuters) -8.92%
08:49PM	Loading…
Sep-14-23 08:49PM	Neumora Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burow Kristina	Director	Nov 14 '23	Buy	11.98	3,357	40,217	4,131,207	Nov 15 06:55 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 14 '23	Buy	11.98	3,357	40,217	4,131,207	Nov 15 06:54 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 13 '23	Buy	11.75	31,653	371,923	4,127,850	Nov 15 06:54 PM
Burow Kristina	Director	Nov 13 '23	Buy	11.75	31,653	371,923	4,127,850	Nov 15 06:55 PM
Burow Kristina	Director	Nov 10 '23	Buy	11.49	17,275	198,481	4,096,197	Nov 13 07:01 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 10 '23	Buy	11.49	17,275	198,481	4,096,197	Nov 13 07:00 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 09 '23	Buy	10.53	31,079	327,262	4,078,922	Nov 13 07:00 PM
Burow Kristina	Director	Nov 09 '23	Buy	10.53	31,079	327,262	4,078,922	Nov 13 07:01 PM
Burow Kristina	Director	Nov 08 '23	Buy	11.03	92,251	1,017,821	4,047,843	Nov 13 07:01 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 08 '23	Buy	11.03	92,251	1,017,821	4,047,843	Nov 13 07:00 PM
Burow Kristina	Director	Nov 07 '23	Buy	11.50	30,192	347,208	3,955,592	Nov 07 07:00 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 07 '23	Buy	11.50	30,192	347,208	3,955,592	Nov 07 06:59 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 06 '23	Buy	11.55	43,082	497,597	3,925,400	Nov 07 06:59 PM
Burow Kristina	Director	Nov 06 '23	Buy	11.55	43,082	497,597	3,925,400	Nov 07 07:00 PM
Burow Kristina	Director	Nov 03 '23	Buy	11.38	22,420	255,140	3,882,318	Nov 07 07:00 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 03 '23	Buy	11.38	22,420	255,140	3,882,318	Nov 07 06:59 PM
Burow Kristina	Director	Sep 29 '23	Buy	13.98	34,560	483,149	3,859,898	Sep 29 06:55 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 29 '23	Buy	13.98	34,560	483,149	3,859,898	Sep 29 06:53 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 28 '23	Buy	13.44	41,951	563,699	3,825,338	Sep 29 06:53 PM
Burow Kristina	Director	Sep 28 '23	Buy	13.44	41,951	563,699	3,825,338	Sep 29 06:55 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 27 '23	Buy	12.31	24,504	301,644	3,783,387	Sep 27 08:18 PM
Burow Kristina	Director	Sep 27 '23	Buy	12.31	24,504	301,644	3,783,387	Sep 27 08:19 PM
Burow Kristina	Director	Sep 26 '23	Buy	11.73	34,000	398,820	3,758,883	Sep 27 08:19 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 26 '23	Buy	11.73	34,000	398,820	3,758,883	Sep 27 08:18 PM
Burow Kristina	Director	Sep 25 '23	Buy	11.22	60,740	681,464	3,724,883	Sep 25 09:37 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 25 '23	Buy	11.22	60,740	681,464	3,724,883	Sep 25 09:38 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 22 '23	Buy	11.14	40,000	445,600	3,664,143	Sep 25 09:38 PM
Burow Kristina	Director	Sep 22 '23	Buy	11.14	40,000	445,600	3,664,143	Sep 25 09:37 PM
AMGEN INC	10% Owner	Sep 19 '23	Buy	17.00	1,764,705	29,999,985	35,368,653	Sep 19 07:52 PM
Burow Kristina	Director	Sep 19 '23	Buy	17.00	1,500,000	25,500,000	3,624,143	Sep 20 06:23 AM
ARCH Venture Partners X, LLC	10% Owner	Sep 19 '23	Buy	17.00	1,500,000	25,500,000	3,624,143	Sep 20 06:16 AM
ARCH Venture Partners X, LLC	10% Owner	Sep 19 '23	Buy	17.00	1,500,000	25,500,000	3,624,143	Sep 20 06:15 AM
Gosebruch Henry O	President & CEO	Sep 19 '23	Buy	12.62	15,000	189,370	15,000	Sep 19 09:47 PM

Open in Screener

SLRN

Acelyrin Inc

Jul 26 • 04:00PM ET

7.00

Dollar change +0.27
Percentage change 4.01	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: IWM VTI IWN VB IBB VBK VXF VTWO IWC SCHA

Index	RUT	P/E	-	EPS (ttm)	-2.46	Insider Own	36.54%	Shs Outstand	97.87M	Perf Week	7.53%
Market Cap	693.21M	Forward P/E	-	EPS next Y	-3.93	Insider Trans	-0.07%	Shs Float	62.84M	Perf Month	81.35%
Income	-240.16M	PEG	-	EPS next Q	-0.78	Inst Own	75.69%	Short Float	10.83%	Perf Quarter	65.09%
Sales	0.00M	P/S	-	EPS this Y	43.31%	Inst Trans	-	Short Ratio	7.30	Perf Half Y	-2.64%
Book/sh	6.52	P/B	1.07	EPS next Y	-27.62%	ROA	-48.23%	Short Interest	6.81M	Perf Year	-70.81%
Cash/sh	6.85	P/C	1.02	EPS next 5Y	-	ROE	-53.53%	52W Range	3.67 - 29.88	Perf YTD	-6.17%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-37.22%	52W High	-76.57%	Beta	1.66
Dividend TTM	-	Quick Ratio	13.27	Sales past 5Y	0.00%	Gross Margin	-	52W Low	90.74%	ATR (14)	0.45
Dividend Ex-Date	-	Current Ratio	13.27	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	71.69	Volatility	6.26% 8.41%
Employees	130	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	28.50
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	80.32%	Payout	-	Rel Volume	1.72	Prev Close	6.73
Sales Surprise	-	EPS Surprise	62.96%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	931.97K	Price	7.00
SMA20	25.43%	SMA50	45.79%	SMA200	3.65%	Trades		Volume	1,601,292	Change	4.01%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-08-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$13
Dec-13-23	Initiated	Wells Fargo	Equal Weight	$11
Dec-08-23	Initiated	Citigroup	Neutral	$8
Sep-13-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19
Sep-05-23	Initiated	H.C. Wainwright	Buy	$44
May-30-23	Initiated	TD Cowen	Outperform
May-30-23	Initiated	Piper Sandler	Overweight	$68
May-30-23	Initiated	Morgan Stanley	Overweight
May-30-23	Initiated	Jefferies	Buy	$31

Jun-05-24 07:00AM	ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024 (GlobeNewswire)
May-29-24 07:00AM	ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024 (GlobeNewswire)
May-15-24 11:54AM	SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024 (InvestorPlace)
May-09-24 08:01AM	ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones (GlobeNewswire)
08:00AM	ACELYRIN, INC. Announces Leadership Transition (GlobeNewswire)
04:05PM	Loading…
Apr-29-24 04:05PM	ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024 (GlobeNewswire)
Mar-28-24 10:53PM	SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023 (InvestorPlace)
04:05PM	ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights (GlobeNewswire)
Mar-27-24 04:01PM	Avalo Acquires Anti-IL-1 mAb and Announces Private Placement Financing of up to $185 Million (GlobeNewswire)
Mar-21-24 11:12AM	ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study (Zacks) -6.49%
Mar-20-24 07:00AM	ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease (GlobeNewswire)
12:39AM	Acelyrin adds proof-of-concept TED data to recent readout pile, cementing challenge to Amgen (FierceBiotech.com)
Mar-11-24 10:04AM	After crushing loss last year, Acelyrin rebounds with psoriatic arthritis victory (FierceBiotech.com) +10.96%
08:02AM	ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis (GlobeNewswire)
08:00AM	ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients (GlobeNewswire)
04:05PM	Loading…
Feb-15-24 04:05PM	ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications (GlobeNewswire) +10.89%
Jan-10-24 11:30AM	ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options (GlobeNewswire) -5.08%
Jan-04-24 09:56AM	Final Deadline Approaching for Acelyrin, Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Acelyrin, Inc. (SLRN) Investors of January 16, 2024 Lead Plaintiff Deadline (GlobeNewswire)
Jan-01-24 09:35AM	Acelyrin (SLRN) Faces Investor Fraud Lawsuit for Allegedly Lying About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
Dec-27-23 10:45AM	ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Dec-20-23 04:30PM	ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors (GlobeNewswire) -5.94%
Dec-19-23 12:13AM	Robbins LLP Reminds Investors of Lawsuit Against Acelyrin, Inc. and Approaching Lead Plaintiff Deadline (GlobeNewswire)
Dec-18-23 04:14PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress-Hagens Berman (GlobeNewswire) -7.49%
Dec-12-23 09:25PM	ACELYRIN, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2024 deadline (GlobeNewswire) +8.51%
Dec-11-23 09:35AM	SLRN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Case (GlobeNewswire) -7.47%
Dec-04-23 03:00PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress - Hagens Berman (GlobeNewswire)
08:00AM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire)
Nov-30-23 04:30PM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire) +5.66%
Nov-28-23 05:55PM	ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2023 deadline (GlobeNewswire) -32.41% +8.16%
01:44PM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire)
07:24AM	Loading…
07:24AM	5 Things to Know Before Markets Open (Investopedia)
Nov-27-23 09:09PM	Acelyrin blames CRO error for shocking phase 3 failure that sent shiver through biotech IPO market (FierceBiotech.com)
04:30PM	ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program (GlobeNewswire)
Nov-20-23 11:01AM	Acelyrin (SLRN) Faces Lawsuit after Allegedly Lying About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
Nov-16-23 06:42PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
04:11PM	ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire)
Nov-07-23 05:11PM	Acelyrin Inc (SLRN) Reports Q3 2023 Financial Results: Key Clinical Trials Progressing (GuruFocus.com) -8.70%
04:05PM	ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Nov-06-23 07:00AM	ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer (GlobeNewswire)
Oct-31-23 04:30PM	ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023 (GlobeNewswire) -10.36%
Oct-18-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Acelyrin, and Clorox and Encourages Investors to Contact the Firm (GlobeNewswire)
Oct-03-23 07:00AM	ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development (GlobeNewswire)
Sep-15-23 05:39PM	Why Acelyrin Stock Plummeted 59% This Week (Motley Fool)
Sep-11-23 04:05PM	ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa (GlobeNewswire) -54.12%
Sep-06-23 07:00AM	ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-15-23 07:22PM	Billionaire Ken Griffin Pours Millions Into These 2 Strong Buy Stocks Heres Why You Might Want to Ride His Coattails (TipRanks) +7.70%
Aug-14-23 04:05PM	ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Aug-07-23 04:30PM	ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023 (GlobeNewswire)
Jul-18-23 07:00AM	ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer (GlobeNewswire)
Jun-15-23 04:05PM	ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
May-09-23 04:10PM	ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
May-05-23 07:08PM	Drug Developer Acelyrin Raises $540 Million in IPO (The Wall Street Journal)

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Becker Daniel J.	Director	Jul 17 '24	Sale	6.86	1	7	2,999	Jul 19 06:18 PM
Lin Shao-Lee	Chief Executive Officer	Apr 01 '24	Sale	6.63	9,961	66,024	1,577,374	Apr 03 06:18 PM
Lin Shao-Lee	Chief Executive Officer	Feb 20 '24	Sale	7.60	15,701	119,403	1,587,335	Feb 22 07:04 PM
Lin Shao-Lee	Chief Executive Officer	Jan 02 '24	Sale	7.41	10,691	79,188	1,603,036	Jan 04 06:09 PM

Open in Screener

ABBV

Abbvie Inc

Jul 26 • 04:00PM ET

185.16

Dollar change +2.99
Percentage change 1.64	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO SPY IVV VTV SCHD XLV VIG VYM VHT

Index	S&P 500	P/E	61.81	EPS (ttm)	3.00	Insider Own	0.10%	Shs Outstand	1.77B	Perf Week	7.45%
Market Cap	326.97B	Forward P/E	15.32	EPS next Y	12.08	Insider Trans	-29.58%	Shs Float	1.76B	Perf Month	8.19%
Income	5.31B	PEG	9.78	EPS next Q	2.94	Inst Own	73.03%	Short Float	0.93%	Perf Quarter	10.68%
Sales	55.00B	P/S	5.94	EPS this Y	-2.40%	Inst Trans	0.10%	Short Ratio	2.97	Perf Half Y	12.13%
Book/sh	4.53	P/B	40.83	EPS next Y	11.44%	ROA	4.20%	Short Interest	16.38M	Perf Year	30.49%
Cash/sh	10.23	P/C	18.10	EPS next 5Y	6.32%	ROE	55.92%	52W Range	135.85 - 186.11	Perf YTD	19.48%
Dividend Est.	6.17 (3.33%)	P/FCF	14.96	EPS past 5Y	-5.77%	ROI	7.39%	52W High	-0.51%	Beta	0.62
Dividend TTM	6.13 (3.31%)	Quick Ratio	0.83	Sales past 5Y	11.76%	Gross Margin	84.51%	52W Low	36.30%	ATR (14)	4.13
Dividend Ex-Date	Jul 15, 2024	Current Ratio	0.94	EPS Y/Y TTM	-21.01%	Oper. Margin	32.12%	RSI (14)	72.04	Volatility	3.14% 2.30%
Employees	50000	Debt/Eq	9.24	Sales Y/Y TTM	-1.83%	Profit Margin	9.65%	Recom	1.83	Target Price	191.47
Option/Short	Yes / Yes	LT Debt/Eq	7.97	EPS Q/Q	-31.94%	Payout	220.33%	Rel Volume	1.26	Prev Close	182.17
Sales Surprise	3.14%	EPS Surprise	3.29%	Sales Q/Q	4.31%	Earnings	Jul 25 BMO	Avg Volume	5.52M	Price	185.16
SMA20	8.54%	SMA50	10.72%	SMA200	14.06%	Trades		Volume	6,947,868	Change	1.64%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-24	Upgrade	HSBC Securities	Hold → Buy	$185
May-17-24	Initiated	Cantor Fitzgerald	Overweight	$200
Jan-29-24	Upgrade	William Blair	Mkt Perform → Outperform
Dec-18-23	Downgrade	HSBC Securities	Buy → Hold
Dec-11-23	Upgrade	Goldman	Neutral → Buy
Nov-09-23	Initiated	Deutsche Bank	Hold	$150
Oct-30-23	Upgrade	Barclays	Equal Weight → Overweight	$160 → $170
Oct-20-23	Resumed	UBS	Neutral	$157 → $150
Sep-29-23	Initiated	Raymond James	Outperform	$177
Jul-25-23	Initiated	William Blair	Mkt Perform
Jul-14-23	Initiated	HSBC Securities	Buy	$167
Apr-05-23	Downgrade	Argus	Buy → Hold
Mar-01-23	Initiated	Guggenheim	Buy	$172
Feb-22-23	Downgrade	Wolfe Research	Outperform → Peer Perform
Feb-10-23	Upgrade	SVB Securities	Underperform → Market Perform	$135 → $153
Nov-18-22	Initiated	Credit Suisse	Outperform	$170
Nov-08-22	Downgrade	Societe Generale	Buy → Hold
Aug-01-22	Downgrade	Atlantic Equities	Overweight → Neutral	$178 → $162
May-23-22	Initiated	SVB Leerink	Underperform	$140
May-06-22	Downgrade	Daiwa Securities	Outperform → Neutral	$150

Show Previous Ratings

Today 04:32AM	AbbVies Q2 2024 net earnings drop to $1.37bn (Pharmaceutical Technology)
03:21AM	Q2 2024 AbbVie Inc Earnings Call (Thomson Reuters StreetEvents)
02:00AM	AbbVie Announces European Commission Approval of SKYRIZI (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (PR Newswire)
Jul-25-24 04:25PM	Why AbbVie Stock Was Cruising Higher on Thursday (Motley Fool)
04:08PM	AbbVie Is About To Have A New Golden Goose As Humira Sales Continue Slowing (Investor's Business Daily)
03:30PM	Loading…
03:30PM	AbbVie (ABBV) Q2 2024 Earnings Call Transcript (Motley Fool)
02:28PM	Stocks on the Move: Nasdaq, Warner Bros, Honeywell and Abbvie (CNBC TV)
01:43PM	Analyst Report: AbbVie Inc. (Morningstar Research)
01:19PM	AbbVie Stock Hits Record High on Demand for Non-Humira Portfolio (Investopedia)
12:38PM	AbbVie Stock Rises on Strong Sales of Immunology Drugs Other Than Humira (Barrons.com)
12:12PM	AbbVie stock gets lift after beating Q2 earnings estimates (Yahoo Finance Video)
11:22AM	New Drug Sales Lift AbbVie Stock (The Wall Street Journal)
10:21AM	AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View (Zacks)
10:18AM	AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs (Benzinga)
09:30AM	AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:30AM	Loading…
09:30AM	Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest? (Zacks)
09:00AM	AbbVie Slides Despite Beating Second-Quarter Views, Raising Guidance (Investor's Business Daily)
08:46AM	AbbVie Stock Is Rising on Strong Earnings. CEO Cites Significant Momentum. (Barrons.com)
08:45AM	AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates (Zacks)
08:30AM	Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected (GlobeNewswire)
07:46AM	Ois n secures funds to advance treatments for age-related ailments (Pharmaceutical Business Review)
07:45AM	Is AbbVie the Best Dividend Stock for You? (Motley Fool)
07:42AM	AbbVie: Q2 Earnings Snapshot (Associated Press Finance)
07:39AM	AbbVie lifts annual profit forecast on strong immunology drug sales (Reuters)
07:36AM	AbbVie Reports Second-Quarter 2024 Financial Results (PR Newswire)
Jul-24-24 06:08PM	Earnings from American & Southwest, Q2 GDP data: What to watch (Yahoo Finance Video)
03:52AM	Pipeline power: Sionnas AbbVie deal could redefine CF therapeutics (Pharmaceutical Technology)
Jul-23-24 08:00AM	AbbVie Inc: An Exploration into Its Intrinsic Value (GuruFocus.com)
07:02AM	AbbVie's EPKINLY Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency (PR Newswire)
Jul-22-24 10:41AM	AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now? (Motley Fool)
09:49AM	Loading…
09:49AM	AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy? (Zacks)
06:34AM	AbbVie (ABBV) Fell as its Arthritis Drug Went Off Patent (Insider Monkey)
Jul-21-24 07:00AM	What To Expect in the Markets This Week (Investopedia)
Jul-19-24 05:45PM	AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts (Zacks)
05:33PM	Tesla, Alphabet, Visa earnings, June PCE data: What to watch (Yahoo Finance Video)
11:13AM	Boehringer Ingelheim offers Humira biosimilar at 92% discount (Pharmaceutical Technology)
Jul-18-24 10:01AM	Earnings Preview: AbbVie (ABBV) Q2 Earnings Expected to Decline (Zacks)
07:43AM	Boehringer cuts price of Humira biosimilar in bid to build use (BioPharma Dive)
06:00AM	GoodRx partners with Boehringer Ingelheim to discount Humira biosimilar (Yahoo Finance)
Jul-17-24 10:53AM	AbbVies Humira loss of exclusivity has been a missed opportunity for competitors (Pharmaceutical Technology)
08:25AM	3 Absurdly Cheap Stocks to Buy and Hold for Years (Motley Fool)
Jul-16-24 01:46PM	Trade Tracker: Rob Sechan sells Bristol Myers and buys more Abbvie (CNBC TV)
10:01AM	Sionna salvages AbbVie assets, teeing up dual combo assault on cystic fibrosis (FierceBiotech.com)
07:10AM	Sionna revives AbbVies cystic fibrosis drugs, eyeing a shot at Vertex (BioPharma Dive)
06:30AM	3 Quantum AI Stocks That Could Redefine Computing (InvestorPlace)
06:00AM	7 Recession-Proof Stocks to Shield Your Portfolio in 2024 (InvestorPlace)
Jul-15-24 12:31PM	3 Spinoff Stocks You Should Buy Now: July 2024 (InvestorPlace)
11:53AM	AbbVie looks to add an eighth indication for JAK inhibitor Rinvoq (Pharmaceutical Technology)
11:13AM	AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU (Zacks)
06:38AM	Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever (Motley Fool)
Jul-14-24 06:30AM	3 Dividend Growth Stocks to Buy and Hold (Motley Fool)
04:27AM	3 High-Yield Dividend Stocks That Still Look Like Bargains (Motley Fool)
Jul-12-24 08:30AM	AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ) in Giant Cell Arteritis (PR Newswire)
Jul-11-24 05:45PM	AbbVie (ABBV) Gains As Market Dips: What You Should Know (Zacks)
10:14AM	AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock? (Zacks)
09:00AM	Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock (Zacks)
Jul-10-24 08:00AM	AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer (PR Newswire)
07:48AM	AbbVie names new R&D head; Arcutis eczema cream approved (BioPharma Dive)
Jul-09-24 08:00AM	Beyond Market Price: Uncovering AbbVie Inc's Intrinsic Value (GuruFocus.com)
07:40AM	The 7 Best Warren Buffett Stocks to Buy in July 2024 (InvestorPlace)
Jul-08-24 05:50AM	The Smartest Dividend Stocks to Buy With $250 Right Now (Motley Fool)
Jul-03-24 03:07PM	AbbVie cuts 2024 profit forecast on R&D expenses (Reuters)
Jul-02-24 04:45PM	7 Dividend Aristocrats That Will Have Investors in High-Yield Heaven (InvestorPlace)
01:10PM	AbbVie, Inc.'s Zymaxid Implicated in Product Liability Lawsuit Due to Risk of Serious Injury and Death (PR Newswire)
08:00AM	AbbVie to Host Second-Quarter 2024 Earnings Conference Call (PR Newswire)
06:24AM	3 Under-the-Radar Biotech Stocks With Blockbuster Potential (InvestorPlace)
Jul-01-24 04:30PM	3 Retirement All-Stars for Steady Growth and Income (InvestorPlace)
01:40PM	Cash Flow Alert: 3 Stocks That Just Raised Their Dividends (InvestorPlace)
10:48AM	2 High-Yielding Healthcare Stocks to Buy With $1,000 in July (Motley Fool)
08:37AM	AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use (Zacks)
08:00AM	Robert A. Michael Assumes Role as AbbVie Chief Executive Officer (PR Newswire)
06:50AM	3 Magnificent Stocks Retirees Can Buy and Hold Forever (Motley Fool)
01:00AM	10 clinical trials to watch in the second half of 2024 (BioPharma Dive)
Jun-30-24 10:13AM	Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn't Discovered Yet (InvestorPlace)
Jun-29-24 03:23PM	How Do These 3 Healthcare Dividend Stocks Deliver Reliable Income And Growth? (Benzinga)
Jun-28-24 04:37PM	How Medicare drug price negotiations could hit pharma stocks (Yahoo Finance Video)
11:02AM	Coherus offloads Humira biosimilar Yusimry for $40m (Pharmaceutical Technology)
08:51AM	AbbVie's (ABBV) Celsius Therapeutics Deal to Boost IBD Presence (Zacks)
06:13AM	7 Dividend Kings to Buy With Your Roth IRA Money in 2024 (InvestorPlace)
04:12AM	AbbVie completes acquisition of Celsius Therapeutics for $250m (Pharmaceutical Technology)
02:00AM	AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma (PR Newswire)
Jun-27-24 11:03AM	FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma (Zacks)
10:37AM	AbbVie sweeps up inflammatory-focused Celsius for $250M cash in summer heat wave (FierceBiotech.com)
09:26AM	AbbVie Acquires Celsius Therapeutics (PR Newswire)
09:00AM	Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? (Zacks)
08:30AM	Introducing All Payment Plans, Powered by Cherry (PR Newswire)
06:22AM	AbbVie expands its IBD prospects with $250M Celsius deal (BioPharma Dive)
05:30AM	Can AbbVie Stock Keep Outpacing the S&P 500? (Motley Fool)
04:32AM	AbbVie gains FDA approval for EPKINLY in follicular lymphoma (Pharmaceutical Technology)
Jun-26-24 07:03PM	U.S. Food and Drug Administration Grants Second Approval for EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma (PR Newswire)
09:05AM	AbbVie (ABBV) Parkinson's Candidate Faces 2nd FDA Rejection (Zacks)
07:00AM	Zealand hauls in $1B off obesity drug data; Curie.bio zeroes in on Series As (BioPharma Dive)
05:12AM	FDA issues complete response to AbbVies NDA for Parkinsons drug (Pharmaceutical Technology)
Jun-25-24 05:45PM	AbbVie (ABBV) Stock Dips While Market Gains: Key Facts (Zacks)
01:27PM	Tech Rally Props Up US Stocks as Nvidia Rallies 5%: Markets Wrap (Bloomberg)
09:58AM	AbbVie's Parkinson's Disease Therapy Hits FDA Roadblock (Benzinga)
08:15AM	AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) (PR Newswire)
08:13AM	ASCO24: AbbVie flexes early success of ADC pipeline in solid tumours (Clinical Trials Arena)
08:00AM	The Art of Valuation: Discovering AbbVie Inc's Intrinsic Value (GuruFocus.com)
04:31AM	3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income (Motley Fool)

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GONZALEZ RICHARD A	EXECUTIVE CHAIRMAN OF BOARD	Jul 17 '24	Option Exercise	77.49	282,845	21,919,048	795,944	Jul 19 04:40 PM
GONZALEZ RICHARD A	EXECUTIVE CHAIRMAN OF BOARD	Jul 17 '24	Sale	175.00	282,845	49,497,875	513,099	Jul 19 04:40 PM
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Mar 20 '24	Sale	176.30	21,082	3,716,757	55,903	Mar 22 05:00 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 18 '24	Option Exercise	61.36	26,110	1,602,110	119,890	Mar 20 05:00 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 18 '24	Sale	178.79	58,949	10,539,508	60,941	Mar 20 05:00 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Mar 01 '24	Option Exercise	61.36	45,700	2,804,152	89,517	Mar 05 05:30 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Mar 01 '24	Sale	177.27	75,680	13,415,503	13,837	Mar 05 05:30 PM
Michael Robert A.	PRES & CHIEF OPERATING OFFICER	Feb 29 '24	Option Exercise	58.30	21,560	1,257,012	167,524	Mar 01 05:50 PM
Michael Robert A.	PRES & CHIEF OPERATING OFFICER	Feb 29 '24	Sale	176.45	68,879	12,153,957	98,645	Mar 01 05:50 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 29 '24	Sale	177.39	9,891	1,754,555	10,397	Mar 01 05:50 PM
Buckbee Kevin K	SVP, CONTROLLER	Feb 29 '24	Sale	176.65	5,144	908,688	6,983	Mar 01 05:50 PM
GONZALEZ RICHARD A	CHAIRMAN OF THE BOARD AND CEO	Feb 28 '24	Sale	177.27	138,616	24,572,458	519,099	Mar 01 05:50 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 23 '24	Option Exercise	137.36	13,753	1,889,115	41,926	Feb 27 05:10 PM
Reents Scott T	EVP, CHIEF FINANCIAL OFFICER	Feb 23 '24	Option Exercise	61.36	14,140	867,630	41,205	Mar 01 05:50 PM
Reents Scott T	EVP, CHIEF FINANCIAL OFFICER	Feb 23 '24	Sale	177.44	14,140	2,509,002	27,065	Mar 01 05:50 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 23 '24	Sale	177.51	13,753	2,441,295	28,173	Feb 27 05:10 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Feb 21 '24	Option Exercise	58.88	52,870	3,112,986	296,814	Feb 23 05:00 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Feb 21 '24	Sale	173.71	52,870	9,184,048	243,944	Feb 23 05:00 PM
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Dec 26 '23	Sale	154.72	2,912	450,545	55,903	Dec 28 05:00 PM
GONZALEZ RICHARD A	CHAIRMAN OF THE BOARD AND CEO	Aug 01 '23	Sale	148.58	60,000	8,914,800	565,294	Aug 02 05:07 PM
GONZALEZ RICHARD A	CHAIRMAN OF THE BOARD AND CEO	Jul 31 '23	Sale	149.15	18,500	2,759,275	625,294	Aug 02 05:07 PM

NMRA

Neumora Therapeutics Inc.

SLRN

Acelyrin Inc

ABBV

Abbvie Inc

Upgrade your FINVIZ experience